Vion (formerly Oncorx) interesting play on Gene Therapy Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Vion (formerly Oncorx) interesting play on Gene Therapy

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: James Reynolds who wrote (53)	5/23/1997 10:37:00 AM
From: Pierre Borczuk	of 370

There is a rumor of an announcement in June that may move this stock up into the 7 range, or even double digits for those overly optimistic.... The stock seemed to have done well when the management went on a road show several months ago, with volume as high as 400,000 shares.... They are unique in their TAPET (bacterial vector for delivering prodrug) They have been involved in Phase III trials of their oncology drug (targets hypoxic cells Promycin) for almost a year now...I suspect this may be the announcement coming up. The drug is being tested against head and neck tumors, but the $$$ would really be if the indications expanded to other solid tumors. As all R&D companies, cash is the issue...they would an infusion from a larger pharmaceutical company, maybe if the news for Promycin is encouraging. Vion appears to be closely tied to Yale University, which is defintely a plus But, the bottom line is , as all these companies are. its risky!

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next